Evidence map›Paper›PMID 41283160›Full record

ArticleAdvances in hematology2025

Treatment Patterns and Outcomes of Patients With Myelodysplastic Syndrome (MDS) by IPSS-R Scores at Academic Cancer Centers.

Connor Willis, Andre Hejazi, Vonetta L Williams, Craig Comperatore, Srinivas Tantravahi, Najla Al Ali, Jeffrey Gilreath, Tibor Kovacsovics, Trang Au, Malinda Tan and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Connor WillisDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA, utah.edu.ORCID https://orcid.org/0000-0001-7895-2747
Andre HejaziDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA, utah.edu.
Vonetta L WilliamsH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA, moffitt.org.
Craig ComperatoreH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA, moffitt.org.
Srinivas TantravahiHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA, utah.edu.
Najla Al AliH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA, moffitt.org.
Jeffrey GilreathHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA, utah.edu.
Tibor KovacsovicsHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA, utah.edu.
Trang AuDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA, utah.edu.
Malinda TanDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA, utah.edu.
Madeline BrendleDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA, utah.edu.
Rami KomrokjiH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA, moffitt.org.
Minkyoung YooDivision of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA, utah.edu.
Mushtaq AshrafNovartis Pharmaceuticals, East Hanover, New Jersey, USA, novartis.com.
Aamir KhakwaniNovartis Pharmaceuticals, East Hanover, New Jersey, USA, novartis.com.
Şerban R IorgaNovartis Pharmaceuticals, East Hanover, New Jersey, USA, novartis.com.
Islam SadekDepartment of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, Duluth, Minnesota, USA, umn.edu.
David A SallmanH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA, moffitt.org.
David StenehjemDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA, utah.edu.

Funding

Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
NCATS NIH HHS UL1 TR002538
6 · The paper itself

Abstract

This study describes treatment patterns and clinical and economic outcomes of patients with myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) risk scores. A retrospective cohort study was conducted including adults diagnosed with MDS between 2010 and 2020 within two academic institutions. A total of 369 patients were included. Hypomethylating agents (HMAs) were used as first-line therapy in 81% (

Identifiers

PMID41283160
PMCPMC12629909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.